Human anti-programmed death-1 (PD-1) antibody possesses the capability to revitalize host T cells and has been an effective therapy for metastatic malignant melanoma (MM). Tcm of CD4+ and CD8+ T cells, but also via a shift to a Th1 phenotype.
malignant melanoma (MM). 3 In contrast, the immune cell composition of the peripheral blood does not necessarily reflect anti-tumor activity because it is influenced by systemic conditions. Despite the fact that a correlation between peripheral blood immune cell composition and anti-tumor activity has not been clearly established, profiling of peripheral blood lymphocytes is attractive because it can potentially provide a frequent and comprehensive analysis of ongoing anti-tumor immune activity in patients. In the case of MM patients, peripheral blood CD16-natural killer (NK) cells are expanded and monocytes decreased compared with healthy subjects (HS). 4, 5 Programmed death-1 (PD-1) is a type I membrane glycoprotein of 50-55 kD expressed on the cell surface of T cells and B cells. 6 In T cells, the expression of PD-1 protein is promoted by antigen presentation. Additionally, in patients with chronic infection or cancer, PD-1 is strongly expressed on exhausted T cells, which are mainly induced by continuous activation signaling. PD-1-expressing T cells receive an inhibitory signal after binding to the ligands PD-L1 and PD-L2, expressed on APC and tumor cells, resulting in the suppression of proliferation, cytokine production, and cytotoxic activity. 7 Human anti-PD-1 antibody has been developed as an anti-tumor agent and exhibits remarkable efficacy in the treatment of MM, non-small cell lung cancer, renal cell carcinoma, lymphoma, and head and neck cancer. 8 The human anti-PD-1 antibody, nivolumab, demonstrated a significant survival benefit in chemotherapy-refractory MM and in first-line chemotherapy for MM compared with dacarbazine. 9, 10 Anti-PD-1 antibody is thought to activate tumor-specific T cells by interfering with the ligation of PD-1 expressed on tumor-specific CD8+
T cells, and PD-L1/L2 on tumor cells. Thus, modulation of PD-1-positive T cells in the tumor site has been thought to be a major aspect of the effectiveness of the PD-1 blockade strategy. 7 In addition, PD-1-expres- 
| MATERIALS AND METHODS

| Patients
A total of 10 patients with advanced MM who were scheduled to receive the anti-PD-1 antibody nivolumab, from January 2015 to
May 2017 at Kyushu University Hospital, Fukuoka, Japan, were reg- 
| Cells
Acid citrate dextrose solution-added peripheral blood (14 mL) was 
| Cytokine production
Selected T-cell subsets, including memory CD4+ or CD8+ T cells and 
| PD-1 expression in each cell population
To assess the exhaustion status of lymphocyte populations in HS and MM patients, we measured the expression of PD-1 in these cells 
| Change in immune cell phenotype after anti-
PD-1 antibody treatment
We then assessed the change in peripheral blood immune cell sub- FrII cells in the total CD4+ population tended to be higher at every treatment cycle (P = 0.055, P = 0.047, P = 0.078, P = 0.13, and P = 0.068, for cycles 1-5, respectively; Figure 4B ).
Samples were obtained at the point when the best clinical responses, either PR or SD (PR/SD), or PD, were confirmed (n = 4 and 7, respectively). Treg FrII cell numbers at the point of PR/SD were similar to pre-treatment levels, while they tended to be higher at the point of PD (P = 0.45 and P = 0.063; Figure 4C ). Figure 4D shows representative flow cytometry scatter plots for the transition Figure 4E,F) .
| Baseline immune cell phenotype and prognosis
Finally, the correlation between baseline immune cell phenotype and prognosis was assessed ( Figure 5A ,B). We divided 9 MM patients into 2 groups based on the median proportion of CD8+ Tem in the total CD8+ population (%CD8+ Tem) prior to nivolumab therapy. We defined patients in whom the proportion of CD8+ Tem was higher than the median as "%CD8+ Tem-high" and those with a lower number of CD8+ Tem cells as "%CD8+ Tem-low". Anti-PD-1 therapy PFS in the %CD8+ Tem-low group was significantly longer than in the % CD8+ Tem-high group (P = 0.016; Figure 5A ). No significant differences in PFS were seen, however, when dividing patients into groups based on the proportions of other subsets of CD8+ and CD4+ T cells. Figure 5B shows the survival curves for patients grouped according to the PD-1 expression level in CD4+ Tem.
Finally, we also examined the significance of memory B cells after 1 cycle of nivolumab in regard to prognosis. Nine patients were divided into 2 groups, "Δ%-switched memory B-high" and "Δ%-switched memory B-low", based on the median difference in proportion following 1 cycle of treatment. In this analysis, we found that the Δ%-switched memory B-high group tended to show worse prognosis ( Figure 5C ).
| DISCUSSION
In the present study, activated CD8+ Tem and Th2 plus Tfh2 
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